| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NPPB; Natriuretic peptides B; Gamma-brain natriuretic peptide |
| Entrez GeneID | 4879 |
| WB Predicted band size | Calculated MW: 15 kDa; Observed MW: 30 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human BNP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于BNP抗体的3篇示例参考文献(内容为模拟概括，非真实文献)：
---
1. **文献名称**：Development of a High-Sensitivity Monoclonal Antibody for BNP Detection in Serum
**作者**：Smith A, et al.
**摘要**：本文报道了一种针对BNP N端表位的单克隆抗体的开发，通过噬菌体展示技术筛选获得。该抗体与BNP结合特异性强，与NT-proBNP无交叉反应，成功应用于化学发光免疫分析法，显著提高了心力衰竭患者血清BNP检测的灵敏度(检测限达5 pg/mL)。
---
2. **文献名称**：Comparative Study of BNP Immunoassays: Impact of Antibody Epitope Selection
**作者**：Zhang L, et al.
**摘要**：研究比较了靶向BNP不同表位(C端活性区 vs. 环状结构区)的抗体对检测结果的影响。发现C端抗体检测受蛋白酶降解干扰更小，而环状结构抗体对完整BNP分子更敏感，为优化临床检测方案提供了依据。
---
3. **文献名称**：BNP Antibody-Based Rapid Test for Point-of-Care Diagnosis of Acute Heart Failure
**作者**：Tanaka K, et al.
**摘要**：开发了一种基于双抗体夹心法的BNP快速检测试纸，使用胶体金标记抗体实现15分钟内定量检测。临床验证显示其与实验室ELISA结果高度一致(r=0.96)，适用于急诊科快速筛查急性心衰患者。
---
**备注**：以上为模拟示例，实际文献需通过PubMed(https://pubmed.ncbi.nlm.nih.gov)或Web of Science等平台，以关键词“BNP antibody”、“immunoassay”、“diagnostic”检索近年高被引论文。真实研究多聚焦于抗体表位优化、检测标准化及临床界值验证等方向。
B-type natriuretic peptide (BNP) is a cardiac hormone primarily secreted by ventricular cardiomyocytes in response to myocardial stretch and pressure overload. It plays a critical role in regulating blood pressure, fluid balance, and cardiovascular homeostasis. As a biomarker, BNP is widely used in diagnosing and monitoring heart failure, with elevated levels correlating with disease severity and adverse outcomes.
BNP antibodies are essential tools in immunoassays (e.g., ELISA, chemiluminescence) for quantifying BNP concentrations in clinical samples. These antibodies target specific epitopes on the BNP molecule, which consists of a 32-amino acid bioactive peptide cleaved from its precursor, proBNP. Developing high-specificity BNP antibodies is challenging due to structural similarities between BNP and related peptides (e.g., atrial natriuretic peptide, NT-proBNP) and the heterogeneity of circulating proBNP fragments.
Most commercial assays employ monoclonal antibodies to enhance specificity, though differences in antibody design (e.g., epitope selection, cross-reactivity profiles) can lead to variability between assays. Standardization remains an issue, complicating result interpretation across platforms. Recent advances aim to improve antibody affinity and stability, enabling more accurate point-of-care testing and personalized management of cardiac disorders. Reliable BNP detection not only aids diagnosis but also guides therapeutic decisions, such as adjusting diuretic or vasodilator regimens, and predicts patient prognosis.
×
